Announced Wed, 19 Aug · 16:18 IST
Indrayani Biotech Q4 and FY26 audited results filed with qualified opinion
Qualified OpinionRevenue DeclineNegative Operating CashflowResults View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.8%1-day move
₹7.55
prior close
₹7.82
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.4-0.5-2.6+3.8+4.5+2.5+5.2+5.7+3.4+29.0+17.9——
Up moveDown movePending
AI summary
Indrayani Biotech reported FY26 consolidated revenue of Rs 13,783.12 lakh (up from Rs 13,022.84 lakh) and net profit of Rs 216.03 lakh versus a loss of Rs 610.75 lakh prior year. Standalone revenue fell sharply to Rs 2,189.78 lakh from Rs 3,776.91 lakh with PAT at Rs 69.97 lakh (vs Rs 144.63 lakh). Auditor issued a qualified opinion on both standalone and consolidated results citing unconfirmed loan, receivable, and trade payable balances.
Likely market impact
Qualified opinion and steep standalone revenue decline flag concerns on audit reliability and core business performance.